5 Biggest Immunotherapy Companies in the World

3. AbbVie Inc. (NYSE:ABBV)

Market Capitalization: $293.90 billion

Number of Hedge Fund Holders: 73

AbbVie Inc. (NYSE:ABBV) is a Chicago, Illinois-based global biopharmaceutical company. AbbVie’s key immunotherapy drug is Imbruvica (ibrutinib), which is a Bruton’s tyrosine kinase (BTK) inhibitor. Imbruvica has been approved for the treatment of several different types of cancer, including mantle cell lymphoma, chronic lymphocytic leukaemia, and Waldenstrom’s macroglobulinemia. The drug works by blocking BTK, which is an enzyme that is involved in the growth and survival of cancer cells. In addition to Imbruvica, AbbVie Inc. (NYSE:ABBV) is also involved in the creation of other immunotherapies for cancer, including antibody-drug conjugates (ADCs) and bispecific antibodies. The stock has an annual dividend yield of 3.97% as of April 28.

Alger Capital shared its outlook on AbbVie Inc. (NYSE:ABBV) in its Q4 2022 investor letter. Here’s what the firm said:

“AbbVie Inc. (NYSE:ABBV) is a global biopharmaceutical company that develops and markets drugs in areas such as immunology. virology and oncology. Recently, the company expanded through the acquisition of Allergan, which added robust growth assets to help offset the loss of U.S. patent protection for Humira, a leading treatment used for rheumatology, and dermatology. gastroenterology, and ophthalmology. While AbbVie reported weak third-quarter revenues across the board, the U.S. Food and Drug Administration (FDA) approved Vraylar (an antipsychotic treatment) in December. Despite concerns around Humira’s loss of patent protection, we believe AbbVie has significantly diversified its revenue and that its launch of Rinvog for psoriatic arthritis and atopic dermatitis could be promising.”